Zelluna ASA Q2 2025 slides: TCR-NK platform advances amid high cash burn

Zelluna ASA's Q2 2025 business update reveals significant progress in its TCR-NK cell therapy platform, with the lead candidate ZI-MA4-1 on track for IND/CTA filing in H2 2025 and first patient dosing in H1 2026, supported by strong patent protection and recent high-value M&A validating the cell therapy market. However, the company faces severe financial challenges, reporting a cash position of MNOK 76 (down from MNOK 135), an operating loss of MNOK -38, and a record quarterly cash burn of MNOK -59, while its stock has significantly declined. Despite management's assertion of a cash runway into Q2 2026, the accelerating burn rate and struggling stock price underscore investor caution, making the next few quarters critical for both clinical advancement and financial stability.

Analysis

Zelluna ASA presents a classic high-risk, high-reward profile for a clinical-stage biotechnology company, characterized by a promising therapeutic platform set against a deteriorating financial position. On the positive side, the company's TCR-NK platform is strategically positioned in the high-growth cell therapy market for solid tumors, supported by a broad concept patent and validated by recent high-value M&A activity, such as AbbVie's $2.1 billion acquisition of an early-stage peer. The clinical development of its lead candidate, ZI-MA4-1, appears on track, with an IND/CTA filing slated for H2 2025 and first patient dosing in H1 2026. However, this clinical promise is severely undermined by the company's financials. The cash position has been nearly halved in a single quarter to MNOK 76, while the operating cash burn accelerated to a record MNOK -59 in Q2 2025. While management asserts this burn rate will decrease and that cash provides a runway into Q2 2026, the current figures imply a runway of just over one quarter, creating significant financing risk. The stock's sharp decline from a 52-week high of 35 NOK to 13.5 NOK reflects deep investor skepticism regarding the company's ability to bridge this financial gap to reach its key value-inflection milestones.

Key Decisions for Investors

• Investors should treat Zelluna as a binary, event-driven holding, where potential upside from its TCR-NK platform and upcoming milestones (MHRA feedback Sept 2025, IND filing H2 2025) is counterbalanced by a significant and immediate financing risk.
• Given the accelerated Q2 cash burn of MNOK -59 against a MNOK 76 cash balance, it is critical to scrutinize management's execution on reducing expenditures, as a dilutive capital raise appears highly probable before reaching key clinical readouts in 2026.
• The discontinuation of the UV1 vaccine program should be viewed as a necessary strategic refocus, but the company's valuation remains entirely dependent on its ability to fund the ZI-MA4-1 program through to the generation of positive clinical data.